scholarly journals Dual local drug delivery of vancomycin and farnesol for mitigation of MRSA infection in vivo – a pilot study

2020 ◽  
Vol 40 ◽  
pp. 38-57
Author(s):  
UC Woelfle ◽  
◽  
T Briggs ◽  
S Bhattacharyya ◽  
H Qu ◽  
...  
2020 ◽  
Vol 26 ◽  
Author(s):  
John Chen ◽  
Andrew Martin ◽  
Warren H. Finlay

Background: Many drugs are delivered intranasally for local or systemic effect, typically in the form of droplets or aerosols. Because of the high cost of in vivo studies, drug developers and researchers often turn to in vitro or in silico testing when first evaluating the behavior and properties of intranasal drug delivery devices and formulations. Recent advances in manufacturing and computer technologies have allowed for increasingly realistic and sophisticated in vitro and in silico reconstructions of the human nasal airways. Objective: To perform a summary of advances in understanding of intranasal drug delivery based on recent in vitro and in silico studies. Conclusion: The turbinates are a common target for local drug delivery applications, and while nasal sprays are able to reach this region, there is currently no broad consensus across the in vitro and in silico literature concerning optimal parameters for device design, formulation properties and patient technique which would maximize turbinate deposition. Nebulizers are able to more easily target the turbinates, but come with the disadvantage of significant lung deposition. Targeting of the olfactory region of the nasal cavity has been explored for potential treatment of central nervous system conditions. Conventional intranasal devices, such as nasal sprays and nebulizers, deliver very little dose to the olfactory region. Recent progress in our understanding of intranasal delivery will be useful in the development of the next generation of intranasal drug delivery devices.


Author(s):  
S Becker ◽  
T Xu ◽  
F Ilchmann ◽  
J Eisler ◽  
B Wolf

This paper presents a concept for an implantable micro-pump based on hydrogen- generating gas cells. The gas-generating cell is separated from the drug reservoir by an expandable latex membrane. The system offers linear drug delivery with flowrates ranging from 8 nl/s to 2 μl/s and a total delivery volume of up to 160 ml. Drugs can be dispensed over a wide backpressure range. The device is scalable based on the size of the gas-producing cell and requires no external energy source. Possible fields of application include in vivo local drug delivery for chemotherapy, diabetes, and pain management.


Circulation ◽  
1997 ◽  
Vol 96 (2) ◽  
pp. 636-645 ◽  
Author(s):  
Dorothea I. Axel ◽  
Wolfgang Kunert ◽  
Christoph Göggelmann ◽  
Martin Oberhoff ◽  
Christian Herdeg ◽  
...  

2010 ◽  
Vol 99 (7) ◽  
pp. 3009-3018 ◽  
Author(s):  
Sheng-Rong Guo ◽  
Zhong-Min Wang ◽  
Ya-Qiong Zhang ◽  
Lei Lei ◽  
Jing-Min Shi ◽  
...  

The Prostate ◽  
2017 ◽  
Vol 77 (13) ◽  
pp. 1356-1365 ◽  
Author(s):  
Werner J. Struss ◽  
Zheng Tan ◽  
Payam Zachkani ◽  
Igor Moskalev ◽  
John K. Jackson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document